|
 |
|
|||||||
|
|||||||||
Copyright © ERS Journals Ltd 1994
Clinical Trial |
The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is characterized by an increased oxidant burden and by a deficiency of glutathione, a major antioxidant, in the lung epithelial lining fluid (ELF). Therefore, a rational therapeutic approach is to reverse the imbalance between oxidants and antioxidants in the lung by enhancing the antioxidant screen. With this background, the aim of our study was to evaluate oral N-acetylcysteine (NAC) as a strategy to augment lung glutathione levels in patients with IPF. Concentrations of total glutathione in bronchoalveolar lavage fluid (BALF) were quantified spectrophotometrically, before and following oral therapy with 3 x 600 mg NAC per day for 5 days, in 17 nonsmoking patients with biopsy-proven IPF. The volume of ELF recovered by BAL was determined using the urea method. Pretherapy, total glutathione levels in ELF in IPF patients were significantly less than normal (187 +/- 36 vs 368 +/- 60 microM), in contrast to levels in BALF (0.99 +/- 0.12 vs 1.18 +/- 0.19 microM). Following therapy with oral NAC, glutathione levels in BALF were 1.54 +/- 0.24 microM (a significant increase compared to pretherapy), whereas the increase in ELF levels (319 +/- 92 microM) did not reach significance. The therapy was well-tolerated, and all routine clinical and bronchoscopic parameters remained unchanged. It is thus feasible and safe to augment deficient lung glutathione levels in patients with IPF; thereby, potentially augmenting pulmonary antioxidant protection.
This article has been cited by other articles:
|
|
 |
|
  A. Watanabe, T. Higami, S. Ohori, T. Koyanagi, S. Nakashima, and T. Mawatari Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1357 - 1363.e2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Behr and J. H. Ryu Pulmonary hypertension in interstitial lung disease Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Ye, Y. Dalavanga, N. Poulakis, S. U. Sixt, J. Guzman, and U. Costabel Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis Eur. Respir. J., May 1, 2008; 31(5): 1030 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Sadegh Soltan-Sharifi, M. Mojtahedzadeh, A. Najafi, M. Reza Khajavi, M. Reza Rouini, M. Moradi, A. Mohammadirad, and M. Abdollahi Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms Human and Experimental Toxicology, September 1, 2007; 26(9): 697 - 703. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H. M. Jansen, W. MacNee, M. Thomeer, B. Wallaert, F. Laurent, et al. High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N. Engl. J. Med., November 24, 2005; 353(21): 2229 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bouros and K. M. Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur. Respir. J., October 1, 2005; 26(4): 693 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Kinnula, C. L. Fattman, R. J. Tan, and T. D. Oury Oxidative Stress in Pulmonary Fibrosis: A Possible Role for Redox Modulatory Therapy Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 417 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sarkar, Y. Sreenivasan, G. T. Ramesh, and S. K. Manna {beta}-D-Glucoside Suppresses Tumor Necrosis Factor-induced Activation of Nuclear Transcription Factor {kappa}B but Potentiates Apoptosis J. Biol. Chem., August 6, 2004; 279(32): 33768 - 33781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mata, A. Ruiz, M. Cerda, M. Martinez-Losa, J. Cortijo, F. Santangelo, A. Serrano-Mollar, A. Llombart-Bosch, and E.J. Morcillo Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats Eur. Respir. J., December 1, 2003; 22(6): 900 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Serrano-Mollar, D Closa, J Cortijo, E J Morcillo, N Prats, M Gironella, J Panes, J Rosello-Catafau, and O Bulbena P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine Thorax, July 1, 2002; 57(7): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Behr, B. Degenkolb, F. Krombach, and C. Vogelmeier Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine Eur. Respir. J., May 1, 2002; 19(5): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-D. WANG, M. YAMAYA, S. OKINAGA, Y.-X. JIA, M. KAMANAKA, H. TAKAHASHI, L.-Y. GUO, T. OHRUI, and H. SASAKI Bilirubin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nemery, A. Bast, J. Behr, P.J.A. Borm, S.J. Bourke, Ph. Camus, P. De Vuyst, H.M. Jansen, V.L. Kinnula, D. Lison, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility Eur. Respir. J., July 1, 2001; 18(32_suppl): 30S - 42s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortijo, M. Cerda-Nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, A. Esteras, A. Llombart-Bosch, and E.J. Morcillo Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats Eur. Respir. J., June 1, 2001; 17(6): 1228 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. ORTOLANI, A. CONTI, A. R. DE GAUDIO, E. MORALDI, Q. CANTINI, and G. NOVELLI The Effect of Glutathione and N-Acetylcysteine on Lipoperoxidative Damage in Patients with Early Septic Shock Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1907 - 1911. [Abstract] [Full Text]
|
|
|
|
|
|
W. W. DOUGLAS, J. H. RYU, and D. R. SCHROEDER Idiopathic Pulmonary Fibrosis . Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1172 - 1178. [Abstract] [Full Text]
|
|
|
|
|
|
R. CORINNE SPRONG, A.M. L. WINKELHUYZEN-JANSSEN, C. J. M. AARSMAN, J. F. L. M. van OIRSCHOT, T. van der BRUGGEN, and B. SWEDER van ASBECK Low-dose N-Acetylcysteine Protects Rats against Endotoxin-mediated Oxidative Stress, But High-dose Increases Mortality Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1283 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Behr, K Maier, B Degenkolb, F Krombach, and C Vogelmeier Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1897 - 1901. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |